Regulation of endothelial cell permeability by platelet-derived extracellular vesicles.
Journal
The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
entrez:
25
5
2019
pubmed:
28
5
2019
medline:
16
5
2020
Statut:
ppublish
Résumé
Platelet (Plt)-derived extracellular vesicles (Plt-EVs) have hemostatic properties similar to Plts. In addition to hemostasis, Plts also function to stabilize the vasculature and maintain endothelial cell (EC) barrier integrity. We hypothesized that Plt-EVs would inhibit vascular EC permeability, similar to fresh Plts. To investigate this hypothesis, we used in vitro and in vivo models of vascular endothelial compromise and bleeding. In the vitro model, Plt-EVs were isolated by ultracentrifugation and characterized for Plt markers and particle size distribution. Effects of Plts and Plt-EVs on endothelial barrier function were assessed by transendothelial electrical resistance measurements and histological analysis of endothelial junction proteins. Hemostatic potential of Plt-EVs and Plts was assessed by multiple electrode Plt aggregometry. Using an in vivo model, the effects of Plts and Plt-EVs on vascular permeability and bleeding were assessed in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice by an established Miles assay of vascular permeability and a tail snip bleeding assay. In the in vitro model, Plt-EVs displayed exosomal size distribution and expressed Plt-specific surface markers. Platelets and Plt-EVs decreased EC permeability and restored EC junctions after thrombin challenge. Multiplate aggregometry revealed that Plt-EVs enhanced thrombin receptor-activating peptide-mediated aggregation of whole blood, whereas Plts enhanced thrombin receptor-activating peptide-, arachidonic acid-, collagen-, and adenosine diphosphate-mediated aggregation. In the in vivo model, Plt-EVs are equivalent to Plts in attenuating vascular endothelial growth factor (VEGF)-A-induced vascular permeability and uncontrolled blood loss in a tail snip hemorrhage model. Our study is the first to report that Plt-EVs might provide a feasible product for transfusion in trauma patients to attenuate bleeding, inhibit vascular permeability, and mitigate the endotheliopathy of trauma.
Sections du résumé
BACKGROUND
Platelet (Plt)-derived extracellular vesicles (Plt-EVs) have hemostatic properties similar to Plts. In addition to hemostasis, Plts also function to stabilize the vasculature and maintain endothelial cell (EC) barrier integrity. We hypothesized that Plt-EVs would inhibit vascular EC permeability, similar to fresh Plts. To investigate this hypothesis, we used in vitro and in vivo models of vascular endothelial compromise and bleeding.
METHODS
In the vitro model, Plt-EVs were isolated by ultracentrifugation and characterized for Plt markers and particle size distribution. Effects of Plts and Plt-EVs on endothelial barrier function were assessed by transendothelial electrical resistance measurements and histological analysis of endothelial junction proteins. Hemostatic potential of Plt-EVs and Plts was assessed by multiple electrode Plt aggregometry. Using an in vivo model, the effects of Plts and Plt-EVs on vascular permeability and bleeding were assessed in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice by an established Miles assay of vascular permeability and a tail snip bleeding assay.
RESULTS
In the in vitro model, Plt-EVs displayed exosomal size distribution and expressed Plt-specific surface markers. Platelets and Plt-EVs decreased EC permeability and restored EC junctions after thrombin challenge. Multiplate aggregometry revealed that Plt-EVs enhanced thrombin receptor-activating peptide-mediated aggregation of whole blood, whereas Plts enhanced thrombin receptor-activating peptide-, arachidonic acid-, collagen-, and adenosine diphosphate-mediated aggregation. In the in vivo model, Plt-EVs are equivalent to Plts in attenuating vascular endothelial growth factor (VEGF)-A-induced vascular permeability and uncontrolled blood loss in a tail snip hemorrhage model.
CONCLUSION
Our study is the first to report that Plt-EVs might provide a feasible product for transfusion in trauma patients to attenuate bleeding, inhibit vascular permeability, and mitigate the endotheliopathy of trauma.
Identifiants
pubmed: 31124890
doi: 10.1097/TA.0000000000002230
pii: 01586154-201906000-00001
pmc: PMC7381393
mid: NIHMS1604530
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
931-942Subventions
Organisme : NIGMS NIH HHS
ID : K23 GM130892
Pays : United States
Références
J Biol Chem. 1997 Feb 28;272(9):6011-7
pubmed: 9038223
N Engl J Med. 2008 Sep 18;359(12):1261-70
pubmed: 18799560
Blood. 1988 Jul;72(1):109-15
pubmed: 3390605
Hematology Am Soc Hematol Educ Program. 2013;2013:656-9
pubmed: 24319247
JAMA. 2015 Feb 3;313(5):471-82
pubmed: 25647203
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
J Vis Exp. 2015 Mar 17;(97):
pubmed: 25867010
Shock. 2015 Apr;43(4):317-21
pubmed: 25565646
Clin Lab Med. 2010 Jun;30(2):475-87
pubmed: 20513565
J Extracell Vesicles. 2014 Aug 06;3:
pubmed: 25147646
Thromb Haemost. 2007 Mar;97(3):425-34
pubmed: 17334510
J Trauma Acute Care Surg. 2012 Dec;73(6 Suppl 5):S431-7
pubmed: 23192066
Int J Biol Sci. 2017 Jul 6;13(7):828-834
pubmed: 28808416
J Extracell Vesicles. 2013 Feb 15;2:
pubmed: 24009893
J Extracell Vesicles. 2015 Dec 17;4:29338
pubmed: 26689982
Eur J Haematol. 1995 Sep;55(3):145-51
pubmed: 7672086
Proc Natl Acad Sci U S A. 2016 Jan 5;113(1):170-5
pubmed: 26699510
JAMA. 2015 May 26;313(20):2078-9
pubmed: 26010642
J Extracell Vesicles. 2015 Dec 31;4:30087
pubmed: 26725829
Blood Adv. 2018 Jul 24;2(14):1696-1704
pubmed: 30030268
Blood. 2014 Oct 2;124(14):2173-83
pubmed: 25082876
J Immunol. 2017 Nov 15;199(10):3559-3570
pubmed: 28978688
Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):125-33
pubmed: 17364477
J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S7-S17
pubmed: 26002267
Circ Res. 2011 May 13;108(10):1284-97
pubmed: 21566224
Transfusion. 2001 Feb;41(2):243-50
pubmed: 11239230
Expert Rev Proteomics. 2009 Jun;6(3):267-83
pubmed: 19489699
Shock. 2018 Mar;49(3):243-248
pubmed: 28858139
Vox Sang. 1987;53(4):214-20
pubmed: 3125686
J Extracell Vesicles. 2018 Jan 15;7(1):1424473
pubmed: 29359036
N Engl J Med. 2013 May 2;368(18):1723-30
pubmed: 23635052
PLoS One. 2010 Dec 17;5(12):e15353
pubmed: 21179422
Front Immunol. 2014 Sep 16;5:442
pubmed: 25278937
Blood. 1999 Dec 1;94(11):3791-9
pubmed: 10572093
J Trauma. 2008 Feb;64(2 Suppl):S21-6; discussion S26-7
pubmed: 18376168
Transfusion. 2016 Mar;56 Suppl 1:S65-75
pubmed: 27001364
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
J Trauma Acute Care Surg. 2016 Apr;80(4):576-84; discussion 584-5
pubmed: 26808040
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Transfus Apher Sci. 2013 Dec;49(3):380-6
pubmed: 23856530
Shock. 2014 May;41 Suppl 1:54-61
pubmed: 24169210
Transfusion. 2016 Mar;56 Suppl 1:S52-64
pubmed: 27001362
J Proteomics. 2010 Sep 10;73(10):1907-20
pubmed: 20601276
Transfusion. 2013 Jan;53 Suppl 1:100S-106S
pubmed: 23301961